Samuel J. Wohlstadter

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases. Wellstat Therapeutics's focus is in the following fields: Oncology Metabolic Diseases Neurodegenerative Diseases Neurometabolic Diseases Wellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials. Wellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc. Wellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including: Chemistry Cell and Molecular Biology Disease Models Translational Biology Clinical Research and Development Project Management Regulatory Quality Assurance and Control Manufacturing Legal and Financial

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases. Wellstat Therapeutics's focus is in the following fields: Oncology Metabolic Diseases Neurodegenerative Diseases Neurometabolic Diseases Wellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials. Wellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc. Wellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including: Chemistry Cell and Molecular Biology Disease Models Translational Biology Clinical Research and Development Project Management Regulatory Quality Assurance and Control Manufacturing Legal and Financial